Sunday, 22 July 2018

Hetero launches anti-retroviral drug in India

01 March 2018 | News

The product has been approved by the Drug Controller General of India and will be marketed and distributed under the brand name ‘TAFERO-EM’.

Image credit- standard.co.ke

Image credit- standard.co.ke

Hyderabad based Hetero Healthcare has recently launched generic anti-retroviral fixed-dose combination (FDC) of ‘Emtricitabine (200mg) and Tenofovir Alafenamide (25mg) in India. The product is the first generic version of Gilead’s Descovy.

The product has been approved by the Drug Controller General of India (DCGI) and will be marketed and distributed under the brand name ‘TAFERO-EM’.

The medication is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 12 years of age and older.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is Telemedicine a key component that will help bring down the disparity in health offerings between rural and urban India?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls